EP Patent

EP4188375A1 — Treatment of migraine

Assigned to Allergan Pharmaceuticals International Ltd · Expires 2023-06-07 · 3y expired

What this patent protects

The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4188375A1
Jurisdiction
EP
Classification
—
Expires
2023-06-07
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Pharmaceuticals International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.